Regeneron Pharmaceuticals, Inc.
REGNFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
14,202
Cost of Revenue
1,971
Gross Profit
12,232
Gross Margin
86.1%
Operating Income
3,991
Operating Margin
28.1%
Net Income
4,413
Net Margin
31.1%
EPS (Basic)
$40.90
EPS (Diluted)
$38.34
EBITDA
5,318
EBITDA Margin
37.4%
2023
12/31/2023
Revenue
13,117
Cost of Revenue
2,245
Gross Profit
10,873
Gross Margin
82.9%
Operating Income
4,349
Operating Margin
33.2%
Net Income
3,954
Net Margin
30.1%
EPS (Basic)
$37.05
EPS (Diluted)
$34.77
EBITDA
4,693
EBITDA Margin
35.8%
2022
12/31/2022
Revenue
12,173
Cost of Revenue
1,705
Gross Profit
10,468
Gross Margin
86.0%
Operating Income
5,386
Operating Margin
44.2%
Net Income
4,338
Net Margin
35.6%
EPS (Basic)
$40.51
EPS (Diluted)
$38.22
EBITDA
5,260
EBITDA Margin
43.2%
2021
12/31/2021
Revenue
16,072
Cost of Revenue
2,724
Gross Profit
13,348
Gross Margin
83.1%
Operating Income
8,947
Operating Margin
55.7%
Net Income
8,075
Net Margin
50.2%
EPS (Basic)
$76.40
EPS (Diluted)
$71.97
EBITDA
9,669
EBITDA Margin
60.2%
2020
12/31/2020
Revenue
8,497
Cost of Revenue
1,356
Gross Profit
7,141
Gross Margin
84.0%
Operating Income
3,577
Operating Margin
42.1%
Net Income
3,513
Net Margin
41.3%
EPS (Basic)
$32.65
EPS (Diluted)
$30.52
EBITDA
4,103
EBITDA Margin
48.3%